An enzyme inhibitor and now drug candidate discovered in the laboratory of Bruce Hammock, University of California, Davis, may help control the often dangerous  side effects of immunotherapy treatments in cancer patients, according to newly published research in the Proceedings of the National Academy of Sciences (PNAS).